NCT05867212

Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 50 (actual)
• Sponsor: Kelley-Ross & Associates, Inc. · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The goal of this demonstration project or observational study is to evaluate the feasibility and acceptability of a pharmacist-managed cabotegravir long acting injectable for PrEP program in a community pharmacy setting. The main question it aims to answer are: * Is the program feasible and acceptable at the end of 1 year of operations? * What are the facilitators and barriers of the program? Participants who want to start the FDA approved cabotegravir long acting injectable medication for PrEP will have the option participating in surveys and a review of their electronic health records. Medication will be administered based on FDA approved labeling guidelines and their PrEP care will be part of standard of care per CDC. Pharmacists who want to provide the service to their patients will have the option of participating in surveys pre and post implementation.

Conditions

• HIV Infections

Interventions

Type	Name	Description
DRUG	Cabotegravir Injection [Apretude]	People who want to get the long acting injectable will have the option in participating in surveys after their visit and have their electronic health records reviewed.

Timeline

• Start date: 2023-05-13
• Primary completion: 2025-04-30
• Completion: 2025-04-30
• First posted: 2023-05-19
• Last updated: 2025-07-29

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study